AR069830A1 - Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos - Google Patents

Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos

Info

Publication number
AR069830A1
AR069830A1 ARP080104914A ARP080104914A AR069830A1 AR 069830 A1 AR069830 A1 AR 069830A1 AR P080104914 A ARP080104914 A AR P080104914A AR P080104914 A ARP080104914 A AR P080104914A AR 069830 A1 AR069830 A1 AR 069830A1
Authority
AR
Argentina
Prior art keywords
factor
methods
coagulation
protein
survival
Prior art date
Application number
ARP080104914A
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Peter Turecek
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR069830A1 publication Critical patent/AR069830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos para incrementar la sobrevida de una proteína de coagulacion por inhibicion de la interaccion con un receptor de depuracion. También se proveen métodos para preparar composiciones que inhiben a los receptores de depuracion de las proteínas de la coagulacion. Asimismo se proporcionan proteínas de la coagulacion conjugadas, inclusive composiciones y formulaciones con las mismas. Reivindicacion 1: Un método para incrementar la sobrevida de una proteína de la coagulacion mediante inhibicion de la interaccion con un receptor de depuracion, donde dicho método comprende los pasos de: (a) modificar una proteína de la coagulacion con un polímero soluble en agua, y (b) administrarle a un mamífero que lo necesita una cantidad eficaz para uso terapéutico de una composicion que comprende al factor de coagulacion modificado; en donde dicha modificacion incrementa la sobrevida de la proteína en la circulacion sanguínea de un mamífero.
ARP080104914A 2007-11-09 2008-11-10 Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos AR069830A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98697507P 2007-11-09 2007-11-09

Publications (1)

Publication Number Publication Date
AR069830A1 true AR069830A1 (es) 2010-02-24

Family

ID=40227950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104914A AR069830A1 (es) 2007-11-09 2008-11-10 Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos

Country Status (10)

Country Link
US (3) US8173597B2 (es)
EP (1) EP2222329A1 (es)
JP (2) JP2011503101A (es)
KR (1) KR20100095441A (es)
AR (1) AR069830A1 (es)
AU (1) AU2008323768A1 (es)
BR (1) BRPI0820271A2 (es)
CA (1) CA2704234A1 (es)
GB (1) GB2467700A (es)
WO (1) WO2009062100A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010146362A2 (en) * 2009-06-16 2010-12-23 The University Of Bath Materials and methods relating to glycosylation
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates
EP2714093A1 (en) * 2011-05-27 2014-04-09 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
HUE039317T2 (hu) 2011-06-10 2018-12-28 Baxalta GmbH Koagulációs betegség kezelése rekombináns VWF adagolásával
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
KR20140083036A (ko) * 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
PT2804623T (pt) 2012-01-12 2019-11-18 Bioverativ Therapeutics Inc Polipéptidos quiméricos do fator viii e suas utilizações
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
BR112015000267B1 (pt) 2012-07-11 2023-01-24 Bioverativ Therapeutics Inc. Proteínas quiméricas, e composição farmacêutica
CN103804451A (zh) * 2012-11-14 2014-05-21 沈阳药科大学 一种由葫芦素b水解制备葫芦素d的方法
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
NZ713904A (en) * 2013-06-28 2022-02-25 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CN116621991A (zh) 2014-01-10 2023-08-22 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
JP6665104B2 (ja) * 2014-04-10 2020-03-13 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 配合培地粉末製剤および細胞培養用液体培地の調製方法
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
CA2953593C (en) * 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
BR112017002090B1 (pt) 2014-08-04 2021-06-01 Csl Limited Composição aquosa de fator viii de coagulação e método de estabilizar uma molécula de fviii
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
CN108779165B (zh) * 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
CN111565741A (zh) * 2017-07-07 2020-08-21 百深公司 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
JP2023500953A (ja) 2019-11-11 2023-01-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1408119A1 (en) * 2001-07-18 2004-04-14 Suntory Limited Method of screening abc protein promoter/inhibitor
IL161251A0 (en) * 2001-10-10 2004-09-27 Neose Technologies Inc Remodeling and glycoconjugation of peptides
WO2004029280A2 (en) 2002-09-24 2004-04-08 Rico Buchli Anti-hla assay and methods
CA2788505C (en) * 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
WO2004084949A2 (en) * 2003-03-20 2004-10-07 Xencor Generating protein pro-drugs using reversible ppg linkages
CA2530725A1 (en) * 2003-03-28 2004-10-07 Biopolymed Inc. Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
ES2512499T3 (es) * 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Fármacos pegilados reversibles
PT2644206T (pt) * 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
SI3130601T1 (sl) 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
WO2006071801A2 (en) * 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
KR101304157B1 (ko) * 2005-06-16 2013-09-06 넥타르 테라퓨틱스 분해가능한 결합을 갖는 컨주게이트 및 이러한 컨주게이트제조에 유용한 고분자 시약
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CA2671676C (en) * 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage

Also Published As

Publication number Publication date
US20130296243A1 (en) 2013-11-07
EP2222329A1 (en) 2010-09-01
US20090247459A1 (en) 2009-10-01
WO2009062100A1 (en) 2009-05-14
US8173597B2 (en) 2012-05-08
CA2704234A1 (en) 2009-05-14
JP2011503101A (ja) 2011-01-27
JP2014141532A (ja) 2014-08-07
AU2008323768A1 (en) 2009-05-14
BRPI0820271A2 (pt) 2015-05-26
GB2467700A (en) 2010-08-11
KR20100095441A (ko) 2010-08-30
US20120322737A1 (en) 2012-12-20
GB201009493D0 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP055531A (es) "nuevos derivados de glicósido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso"
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY27760A1 (es) Nuevos derivados de pirrolidinio.
CL2008001194A1 (es) Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
GT200500275A (es) Nuevos herbicidas
ECSP10010693A (es) Compuestos pirazólicos 436
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
AR047529A1 (es) Compuestos de quinolina sustituidos
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
UY29036A1 (es) Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica
BRPI0413742B8 (pt) composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BR0012951A (pt) Agonistas de retinóides seletivos
AR033957A1 (es) Nuevos compuestos
CR8384A (es) Metodos y composiciones para la inhibicion de selectina

Legal Events

Date Code Title Description
FB Suspension of granting procedure